Press releases

30
Jun 2022
09:00 E.S.T.

Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence

Read more
28
Jun 2022
20:30 E.S.T.

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Read more
28
Jun 2022
20:05 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022

Read more
23
May 2022
20:30 E.S.T.

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022

Read more
16
May 2022
12:30 E.S.T.

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

Read more
12
May 2022
20:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

Read more
5
May 2022
20:30 E.S.T.

Cellectis to Report First Quarter 2022 Financial Results

Read more
5
May 2022
20:00 E.S.T.

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Read more
28
Apr 2022
12:00 E.S.T.

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Read more
27
Apr 2022
08:00 E.S.T.

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US